


Bellmunt J, de Wit R, Vaughn DJ, et al. Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs. investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC). Abstract 410. Presented at: ASCO Genitourinary Cancers Symposium; February 8–10, 2018; San Francisco, California.


